Tools · ABT
Abbott Laboratories, taken apart.
Four panels built from the reported annual accounts, then the rest of the engine. Every figure below is Abbott Laboratories’s own filing, not an estimate of ours.
Income statement
Revenue mix
Peer comparison
Analyst ratings
What if I had bought
Sentiment
Chart patterns
Income statement, four years
Read across, not down. Each line is shown for four fiscal years, so the direction matters more than any single column.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B |
| Cost of revenue | $19.32B | $18.71B | $17.98B | $19.14B |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B |
| Operating expenses | $16.96B | $16.42B | $15.66B | $16.15B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B |
| Diluted EPS | 3.72 | 7.64 | 3.26 | 3.91 |
Net income moved -5.9% across these years while earnings per share moved -4.9% — more than the profit itself, because the share count changed. Profit split fewer ways is not the same as more profit.
The rest of the engine
The panels above are built from filings. These run against the live engine.
/screener
Screener
Preset screens run against the live universe
Value, growth, quality and momentum presets
/markets
Markets
Indices, sector performance and the yield curve
One request per panel, cached for ten minutes
/dcf-calculator
DCF calculator
Value the company on the cash it produces
The projection period and terminal growth are yours
/watchlist
Watchlist
Follow symbols with a live price and day change
Needs an account
/portfolio
Portfolio
Holdings with unrealised profit and loss
Totalled per currency — needs an account
/learn
Learn
Guides, a glossary and the assistant
Explains the scorecard this site actually runs